{"id":128436,"name":"SUMITOMO PHARMA AMERICA (FORMERLY SUNOVION PHARMACEUTICALS, INC.)","slug":"sumitomo-pharma-america-formerly-sunovion-pharmaceuticals-inc","state":"MA","country":"United States of America","description":"Research-based pharmaceutical company","totalSpending":1370000,"filings":26,"yearlySpending":[{"year":2018,"income":150000},{"year":2019,"income":160000},{"year":2020,"income":220000},{"year":2021,"income":240000},{"year":2022,"income":240000},{"year":2023,"income":300000},{"year":2024,"income":60000}],"issues":[{"code":"PHA","display":"Pharmacy"}],"firms":["KING & SPALDING LLP"],"lobbyists":["DAVID FARBER","SCOTT DZIENGELSKI"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE"],"sampleDescriptions":["Issues related to inclusion of prescription drugs within Essential Health Benefit and mental health coverage expansion","Issues related to inclusion of prescription drugs within Essential Health Benefit and mental health coverage expansion","Issues related to inclusion of prescription drugs within Essential Health Benefit and mental health coverage expansion","Issues related to inclusion of prescription drugs within Essential Health Benefit and mental health coverage expansion","Issues related to drug pricing and six protected classes"]}